Brookside Casa | |
17858 Brookside Rd Barnett MO 65011-3023 | |
(573) 378-2266 | |
(573) 378-2267 |
Full Name | Brookside Casa |
---|---|
Speciality | Community/behavioral Health |
Location | 17858 Brookside Rd, Barnett, Missouri |
Authorized Official Name and Position | Densie L Spotila (ADMINISTRATOR) |
Authorized Official Contact | 5733782266 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Brookside Casa 17858 Brookside Rd Barnett MO 65011-3023 Ph: (573) 378-2266 | Brookside Casa 17858 Brookside Rd Barnett MO 65011-3023 Ph: (573) 378-2266 |
NPI Number | 1215056437 |
---|---|
Provider Enumeration Date | 03/28/2007 |
Last Update Date | 07/02/2008 |
Identifier | Type | State | Issuer |
---|---|---|---|
1215056437 | NPI | - | NPPES |
856254107 | Medicaid | MO |
News Archive
Regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with docetaxel, according to research presented at the NCRI Festival.
Cooking vegetables in the sofrito with extra virgin olive oil favors the absorption and release of bioactive compounds of its traditional ingredients, according to the study conducted by a research team of the Faculty of Pharmacy and Food Sciences at the University of Barcelona, from the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre and the Diabetes and Associated Metabolic Diseases Networking Biomedical Research, led by the tenure lecturer Rosa M. Lamuela.
Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced today that it has signed a multi-year strategic development agreement with The University of Texas MD Anderson Cancer Center, an internationally renowned cancer research, treatment and education center.
MedAssets, Inc. today announced results for its first quarter ended March 31, 2011.
Pearl Therapeutics Inc. today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil Aerolizer in patients with moderate-to-severe COPD.
› Verified 3 days ago